Sanofi Tops CNS Summit’s 2026 Digital Innovation Index

Sanofi leads the pharmaceutical rankings

The index ranks the top 30 pharmaceutical companies according to publicly reported digital innovation initiatives and investments made from July 2025 through July 2026. Sanofi took the top position, followed by Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA in the top 10.

The 2026 rankings were announced on the CNS Summit 2026 main stage at Encore Boston Harbor. Now in its 11th year, the index was developed in collaboration with IDEA Pharma, a division of SAI MedPartners.

Category leaders span the drug development process

Roche led the commercial category, while Novo Nordisk ranked first in clinical development. Recursion was the leader in research.

Sanofi’s top three placement in all three categories points to the breadth of its digital innovation activity across the pharmaceutical development process. Emmanuel Frenehard, Sanofi’s chief digital officer, said the ranking reflects a shift toward “a connected system spanning research, clinical development and commercial operations.”

“This is what allows us to move beyond AI experimentation to AI that delivers impact at scale, so that scientific breakthroughs reach patients faster,” Frenehard said.

The index focuses on how innovation is embedded

CNS Summit Chairman and Chief Curator Dr. Amir Kalali said digital innovation is becoming increasingly important in research and development, adding that the organization supports the index as an independent effort to benchmark life science companies.

According to Dr. Alexander Gray, IDEA Pharma’s chief medical officer and senior vice president of consulting, the results reflect a changing definition of digital leadership in the pharmaceutical industry. He said leadership is “not only about adopting new technologies but also about embedding them into the decisions that shape candidate selection, drug development and patient care.”

The full 2026 rankings and white paper are available through the CNS Summit and IDEA Pharma websites. For pharmaceutical companies, the findings provide a benchmark based on publicly reported initiatives and investments, while the category results show how digital activity is being assessed across research, clinical development and commercial operations.